Alpha Crest Capital Management LLC Incyte Corp Transaction History

Alpha Crest Capital Management LLC

$0
Q4 2022

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $220,114 - $275,592	3,326 Added 10.21%	35,900 $2.39 Million
Q2 2022 Aug 11, 2022	BUY	$66.18 - $83.18 $1.55 Million - $1.95 Million	23,408 Added 255.38%	32,574 $2.48 Million
Q1 2022 May 12, 2022	SELL	$66.02 - $79.71 $2.18 Million - $2.63 Million	-33,004 Reduced 78.26%	9,166 $728,000
Q4 2021 Feb 09, 2022	BUY	$63.34 - $74.11 $49,151 - $57,509	776 Added 1.87%	42,170 $3.1 Million
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $605,532 - $740,888	8,818 Added 27.07%	41,394 $2.85 Million
Q2 2021 Aug 12, 2021	BUY	$79.87 - $87.53 $1.35 Million - $1.48 Million	16,880 Added 107.54%	32,576 $2.74 Million
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $485,691 - $642,094	-6,389 Reduced 28.93%	15,696 $1.28 Million
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $928,832 - $1.12 Million	11,504 Added 108.72%	22,085 $1.92 Million
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $900,125 - $1.16 Million	10,581 New	10,581 $950,000
Q2 2020 Aug 12, 2020	SELL	$74.18 - $108.93 $1.74 Million - $2.55 Million	-23,447 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$63.18 - $85.97 $235,155 - $319,980	-3,722 Reduced 13.7%	23,447 $1.72 Million
Q4 2019 Feb 12, 2020	SELL	$73.04 - $95.72 $220,069 - $288,404	-3,013 Reduced 9.98%	27,169 $2.37 Million
Q3 2019 Nov 12, 2019	BUY	$72.82 - $86.52 $478,791 - $568,869	6,575 Added 27.85%	30,182 $2.24 Million
Q2 2019 Aug 12, 2019	BUY	$73.52 - $88.7 $1.4 Million - $1.69 Million	19,026 Added 415.32%	23,607 $2.01 Million
Q1 2019 May 10, 2019	BUY	$63.56 - $88.17 $291,168 - $403,906	4,581 New	4,581 $394,000

Others Institutions Holding INCY

# of Institutions

645

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.

Account